Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 8.1 | 1.89% | 0.15 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical AGLE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 1.89% | |
| Crossed Above 20 DMA | Bullish | 1.89% | |
| Crossed Above 50 DMA | Bullish | 1.89% | |
| Up 3 Days in a Row | Strength | 1.89% | |
| 50 DMA Resistance | Bearish | 7.28% | |
| Fell Below 50 DMA | Bearish | 11.72% | |
| MACD Bearish Centerline Cross | Bearish | 11.72% | |
| 50 DMA Support | Bullish | 5.06% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.06% | |
| NR7 | Range Contraction | 5.06% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 20 DMA Support | about 2 hours ago |
| Rose Above Previous Day's High | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Up 2% | about 3 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
Aeglea BioTherapeutics, Inc. Description
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Solid Tumors Enzymes Metabolism Organic Chemistry Inborn Errors Of Metabolism Oxidative Stress Cystinuria Homocystinuria
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.38 |
| 52 Week Low | 5.1 |
| Average Volume | 170,140 |
| 200-Day Moving Average | 7.80 |
| 50-Day Moving Average | 7.68 |
| 20-Day Moving Average | 7.79 |
| 10-Day Moving Average | 7.78 |
| Average True Range | 0.48 |
| ADX | 9.64 |
| +DI | 25.38 |
| -DI | 22.76 |
| Chandelier Exit (Long, 3 ATRs ) | 7.36 |
| Chandelier Exit (Short, 3 ATRs ) | 8.48 |
| Upper Bollinger Band | 8.59 |
| Lower Bollinger Band | 6.99 |
| Percent B (%b) | 0.6 |
| BandWidth | 20.48 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0255 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.71 | ||||
| Resistance 3 (R3) | 8.66 | 8.35 | 8.58 | ||
| Resistance 2 (R2) | 8.35 | 8.16 | 8.38 | 8.54 | |
| Resistance 1 (R1) | 8.15 | 8.04 | 8.25 | 8.20 | 8.50 |
| Pivot Point | 7.85 | 7.85 | 7.90 | 7.87 | 7.85 |
| Support 1 (S1) | 7.65 | 7.66 | 7.75 | 7.70 | 7.40 |
| Support 2 (S2) | 7.34 | 7.54 | 7.37 | 7.36 | |
| Support 3 (S3) | 7.14 | 7.34 | 7.32 | ||
| Support 4 (S4) | 7.19 |
